UB Paderborn / Katalog / Suche / in CDI

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2017, Vol.23 (10), p.779-781

2017

Link zum Volltext

Verfügbarkeit prüfen

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

The Lancet (British edition), 2021-09, Vol.398 (10306), p.1157-1169

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 144

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(137)

Publikationsform

Artikel
(143)
Berichte
(1)

Sprache

Englisch
(144)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010

R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

Emergence of carbapenemase-producing Acinetobacter ursingii in The Netherlands

Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature

Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011

High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2

Cyclosporin in Cell Therapy for Cardiac Regeneration

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM‐R2 STUDY INCLUDING 2‐YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM'S MACROGLOBULINEMIA

Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia

MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes

Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patients

SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITY

Effects of anti‐CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro

Mixed autoimmune haemolysis in a SLE patient due to aspecific and anti-Jka autoantibodies; case report and review of the literature

Successful treatment of subcutaneously disseminated aspergillosis with caspofungin acetate in an allogeneic peripheral blood stem cell transplantation patient

Serum levels of soluble CD27 in renal transplant recipients

Emergence of carbapenemase-producing Acinetobacter ursingii in The Netherlands

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Suchergebnisse filtern